COOH-terminal domain of p53 modulates p53-mediated transcriptional transactivation, cell growth, and apoptosis

Cancer Research

Volumn 59, Issue 4, 1999, Pages 843-848

  Zhou, Xiaoling ^a   Wang, Xin Wei ^a   Xu, Lixin ^a   Hagiwara, Koichi ^a   Nagashima, Makoto ^a   Wolkowicz, Roland ^b   Zurer, Irit ^b   Rotter, Varda ^b   Harris, Curtis C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

APOPTOSIS; ARTICLE; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL CYCLE; CELL GROWTH; CONTROLLED STUDY; DNA BINDING; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; OLIGOMERIZATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CELL DIVISION; CELLS, CULTURED; DNA; HUMANS; MUTATION; STRUCTURE-ACTIVITY RELATIONSHIP; TRANS-ACTIVATION (GENETICS); TUMOR SUPPRESSOR PROTEIN P53;

EID: 0345059361     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V., and Kastan, M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA, 89: 7491-7495, 1992.
2. Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K., and Vogelstein, B. Suppression of human colorectal carcinoma cell growth by wild-type p53, Science, 249: 912-915, 1990.
3. De Fromentel, C. C., and Soussi, T. TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer, 4: 1-15, 1992.
4. Mercer, W. E., Shields, M. T., Lin, D., Appella, E., and Ullrich, S. J. Growth suppression induced by wild-type p53 protein is accompanied by selective down regulation of proliferating cell nuclear antigen (PCNA) expression. Proc. Natl. Acad. Sci. USA, 88: 1958-1962, 1991.
5. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
6. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K., and Elledge, S. J. The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75: 805-816, 1993.
7. Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., and Fornace, A. J., Jr. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in Ataxia-Telangiectasia. Cell, 71: 587-597, 1992.
8. Shaw, P., Bovey, R., Tardy, S., Sahli, R., Sordat, B., and Costa, J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc. Natl. Acad. Sci. USA, 89: 4495-4499, 1992.
9. Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., and Wyllie, A. H. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (Lond.), 362: 849-852, 1993.
10. Ludwig, R. L., Bates, S., and Vousden, K. H. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol. Cell. Biol., 16: 4952-4960, 1996.
11. Wang, X. W., Gibson, M. K., Vermeulen, W., Yeh, H., Forrester, K., Sturzbecher, H. W., Hoeijmakers, J. H. J., and Harris, C. C. Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Res., 55: 6012-6016, 1995.
12. Gu, W., and Roeder, R. G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell, 90: 595-606, 1997.
13. Selivanova, G., Iotsova, V., Okan, I., Fritsche, M., Strom, M., Groner, B., Grafstrom, R. C., and Wiman, K. G. Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat. Med., 3: 632-638, 1997.
14. Reed, M., Woelker, B., Wang, P., Wang, Y., Anderson, M. E., and Tegtmeyer, P. The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation. Proc. Natl. Acad. Sci. USA, 92: 9455-9459, 1995.
15. Bakalkin, G., Yakovleva, T., Selivanova, G., Magnusson, K. P., Szekely, L., Kiseleva, E., Klein, G., Terenius, L., and Wiman, K. G p53 binds single-stranded DNA ends and catalyzes DNA renaturation and strand transfer. Proc. Natl. Acad. Sci. USA, 91: 413-417, 1994.
16. Jayaraman, J., and Prives, C. Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell, 81: 1021-1029, 1995.
17. Wang, X. W., Vermeulen, W., Coursen, J. D., Gibson, M., Lupold, S. E., Forrester, K., Xu, G., Elmore, L., Yeh, H., Hoeijmakers, J. H. J., and Harris, C. C. The XPB and XPD helicases are components of the p53-mediated apoptosis pathway. Genes Dev., 10: 1219-1232, 1996.
18. 1 cyclin-dependent kinases. Nature (Lond.), 376: 88-91, 1995.
19. Lee, S., Elenbaas, B., Levine, A., and Griffith, J. p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell, 81: 1013-1020, 1995.
20. Pariat, M., Carillo, S., Molinari, M., Salvat, C., Debussche, L., Bracco, L., Milner, J., and Piechaczyk, M. Proteolysis by calpains: a possible contribution to degradation of p53. Mol. Cell. Biol., 17: 2806-2815, 1997.
21. Kim, E., Albrechtsen, N., and Deppert, W. DNA-conformation is an important determinant of sequence-specific DNA binding by tumor suppressor p53. Oncogene. 15: 857-869, 1997.
22. Hupp, T. R., Meek, D. W., Midgley, C. A., and Lane, D. P. Regulation of the specific DNA binding function of p53. Cell, 71: 875-886, 1992.
23. Anderson, M. E., Woelker, B., Reed, M., Wang, P., and Tegtmeyer, P. Reciprocal interference between the sequence-specific core and nonspecific C-terminal DNA binding domains of p53: implications for regulation. Mol. Cell. Biol., 17: 6255-6264, 1997.
24. Foord, O. S., Bhattacharya, P., Reich, Z., and Rotter, V. A DNA binding domain is contained in the C-terminus of wild type p53 protein. Nucleic Acids Res., 19: 5191-5198, 1991.
25. Bayle, J. H., Elenbaas, B., and Levine, A. J. The carboxyl-terminal domain of the p53 protein regulates sequence-specific DNA binding through its nonspecific nucleic acid-binding activity. Proc. Natl. Acad. Sci. USA, 92: 5729-5733, 1995.
26. Miyashita, T., and Reed, J. C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell, 80: 293-299, 1995.
27. Rajah, R., Valentinis, B., and Cohen, P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53-and IGF-independent mechanism. J. Biol. Chem. 272: 12181-12188, 1997.
28. Hupp, T. R., and Lane, D. P. Allosteric activation of latent p53 tetramers. Curr. Biol., 4: 865-875, 1994.
29. Wolkowicz, R., Peled, A., Elkind, N. B., and Rotter, V. Augmented DNA-binding activity of p53 protein encoded by a carboxyl-terminal alternatively spliced mRNA is blocked by p53 protein encoded by the regularly spliced form. Proc. Natl. Acad. Sci. USA, 92: 6842-6846, 1995.
30. Selvakumaran, M., Lin, H. K., Miyashita, T., Wang, H. G., Krajewski, S., Reed, J. C., Hoffman, B., and Liebermann, D. Immediate early up-regulation of Bax expression by p53 but not TGF β1: a paradigm for distinct apoplotic pathways. Oncogene, 9: 1791-1798, 1994.
31. Caelles, C., Helmberg, A., and Karin, M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature (Lond.), 370: 220-223, 1994.
32. Haupt, Y., Rowan, S., Shaulian E., Vousden, K. H., and Oren, M. Induction of apoptosis in HeLa cells by transactivation-deficient p53. Genes Dev., 9: 2170-2183, 1995.
33. Wang, X. W., Yeh, H., Schaeffer, L., Roy, R., Moncollin, V., Egly, J. M., Wang, Z., Freidberg, E. C., Evans, M. K., Taffe, B. G., Bohr, V. A., Weeda, G., Hoeijmakers, J. H., Forrester, K., and Harris, C. C. p53 modulation of TFIIH-associated nucleotide excision repair activity. Nat. Genet., 10: 188-195, 1995.
34. Wang, X. W., Forrester, K., Yeh, H., Feitelson, M. A., Gu, J. R., and Harris, C. C. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl. Acad. Sci. USA. 91: 2230-2234, 1994.
35. Bakalkin, G., Selivanova, G., Yakovleva, T., Kiseleva, E., Kashuba, E., Magnusson, K. P., Szekely, L., Klein, G., Terenius, L., and Wiman, K. G. p53 binds single-stranded DNA ends through the C-terminal domain and internal DNA segments via the middle domain. Nucleic Acids Res., 23: 362-369, 1995.
36. Greenblatt, M. S., Grollman, A. P., and Harris, C. C. Deletions and insertions in the p53 tumor suppressor gene in human cancers: confirmation of the DNA polymerase slippage/misalignment model. Cancer Res., 56: 2130-2136, 1996.
37. Hainaut, P., Hernandez, T., Robinson, A., Rodriguez-Tome, P., Flores, T., Hollstein, M., Harris, C. C. and Montesano, R. IARC database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualization tools. Nucleic Acids Res. 26: 205-213, 1998.
38. Shibagaki, I., Tanaka, H., Shimada, Y., Wagata, T., Ikenaga, M., Imamura, M., and Ishizaki, K. p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma. Clin. Cancer Res., 1: 769-773, 1995.
39. Honda, T., Kato, H., Imamura, T., Gima, T., Nishida, J., Sasaki, M., Hoshi, K., Sato, A., and Wake, N. Involvement of p53 gene mutations in human endometrial carcinomas. Int. J. Cancer, 53: 963-967, 1993.
40. Okamoto, A., Sameshima, Y., Yamada, Y., Teshima, S., Terashima, Y., Terada, M., and Yokota, J. Allelic loss on chromosome 17p and p53 mutations in human endometrial carcinoma of the uterus. Cancer Res., 51: 5632-5635, 1991.
41. Lazar, V., Grandjouan, S., Bognel, C., Couturier, D., Rougier, P., Bellet, D., and Bressac-de Paillerets, B. Accumulation of multiple mutations in tumour suppressor genes during colorectal tumorigenesis in HNPCC patients. Hum. Mol. Genet., 3: 2257-2260, 1994.
42. Williamson, M. P., Elder, P. A., and Knowles, M. A. The spectrum of TP53 mutations in bladder carcinoma. Genes Chromosomes Cancer, 9: 108-118, 1994.
43. Buckbinder, L., Talbott, R., Velasco-Miguel, S., Takenaka, I., Faha, B., Seizinger, B. R., and Kley, N. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature (Lond.), 377: 646-649, 1995.
44. El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., and Vogelstein, B. Definition of a consensus binding site for p53. Nat. Genet., 1: 45-49, 1992.
45. Chen, J.-Y., Funk, W. D., Wright, W. E., Shay, J. W., and Minna, J. D. Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences. Oncogene, 8: 2159-2166, 1993.
46. Crook, T., Marston, N. J., Sara, E. A., and Vousden, K. H. Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell, 79: 817-827, 1994.
47. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
48. Fritsche, M., Haessler, C., and Brandner, G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene, 8: 307-318, 1993.
49. Nelson, S. L., Giver, C. R., and Grosovsky, A. J. Spectrum of X-ray-induced mutations in the human hprt gene. Carcinogenesis (Lond.), 15: 495-502, 1994.
50. Lane, D. P. Cancer, p53, guardian of the genome. Nature (Lond.), 358: 15-16, 1992.
51. Miyashita, T., Krajewski, S., Krajewska, M., Wang, H. G., Lin, H. K., Liebermann, D. A., Hoffman, B., and Reed, J. C. Tumor suppressor p53 is a regulator of hcl-2 and bax gene expression in vitro and in vivo. Oncogene, 9: 1799-1805, 1994.
52. Almog, N., Li, R., Peled, A., Schwartz, D., Wolkowicz, R., Goldfinger, N., Pei, H., and Rotter, V. The murine C'-terminally alternatively spliced form of p53 induces attenuated apoptosis in myeloid cells. Mol. Cell. Biol., 17: 713-722, 1997.
53. Meek, D. W. Post-translational modification of p53. Semin. Cancer Biol., 5: 203-210, 1994.
54. Funk, W. D., Pak, D. T., Karas, R. H., Wright, W. E., and Shay, J. W. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol. 12: 2866-2871, 1992.
55. Schaeffer, L., Roy, R., Humbert, S., Moncollin, V., Vermeulen, W., Hoeijmakers, J. H., Chambon, P., and Egly, J. M. DNA repair helicase: a component of BTF2 (TFIIH) basic transcription factor. Science (Washington, DC), 260: 58-63, 1993.
56. Weeda, G., van Ham, R. C., Vermeulen, W., Bootsma, D., van der Eb, A. J., and Hoeijmakers, J. H. A presumed DNA helicase encoded by ERCC-3 is involved in the human repair disorders xeroderma pigmentosum and Cockayne's syndrome. Cell, 62: 777-791, 1990.
57. Lu, H., Fisher, R. P., Bailey, P., and Levine, A. J. The CDK7-cycH-p36 complex of transcription factor IIH phosphorylates p53. enhancing its sequence-specific DNA binding activity in vitro. Mol. Cell. Biol., 17: 5923-5934, 1997.
58. Xiao, H., Pearson, A., Coulombe, B., Truant, R., Zhang, S., Regier, J. L., Triezenberg, S. J., Reinberg, D., Flores, O., Ingles, C. J., and Greenblatt, J. Binding of basal transcription factor TFIIH to the acidic activation domains of VPI6 and p53. Mol. Cell. Biol., 14: 7013-7024, 1994.
59. Harris, C. C., Grady, H., and Svoboda, D. Alterations in pancreatic and hepatic ultrastructure following acute cycloheximide intoxication. J. Ultrastruct. Res., 22: 240-251, 1968.
60. Martin, S. J. Protein or RNA synthesis inhibition induces apoptosis of mature human CD4+ T cell blasts. Immunol Lett . 35: 125-134, 1993.
61. Chen, X., Ko, L. J., Jayaraman, L., and Prives, C. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev., 10: 2438-2451, 1996.
62. Rowan, S., Ludwig, R. L., Haupt, Y., Bates, S., Lu, X., Oren, M., and Vousden, K. H. Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J., 15: 827-838, 1996.
63. Sakamuro, D., Sabbatini, P., White, E., and Prendergast, G. C. The polyproline region of p53 is required to activate apoptosis but not growth arrest. Oncogene, 15: 887-898, 1997.
64. Forrester, K., Lupold, S. E., Ott, V. L., Chay, C. H., Band, V., Wang, X. W., and Harris, C. C. Effects of p53 mutants on wild-type ,53-mediated transactivation are cell type dependent. Oncogene, 10: 2103-2111, 1995.
65. Farmer, G., Bargonetti, J., Zhu, H., Friedman, P., Prywes, R., and Prives, C. Wildtype p53 activates transcription in vitro. Nature (Lond.), 358: 83-86, 1992.
66. Kulesz-Martin, M. F., Lisafeld, B., Huang, H., Kisiel, N. D., and Lee, L. Endogenous p53 protein generated from wild-type alternatively spliced p53 RNA in mouse epidermal cells. Mol. Cell. Biol., 14: 1698-1708, 1994.